clinical trial · NCT06674941
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
Amgen·phase1·completed·n = 44
Healthy VolunteersTeprotumumab
brief summary
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and to assess the PK of teprotumumab delivered by syringe pump and by an injection device in non-Japanese participants.
started
Mar 24, 2023
primary completion
Nov 14, 2023
completion
Nov 14, 2023
last updated
Nov 5, 2024
official title
A Phase 1, Open-label, Single-dose Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol